EN
Home/Canada/Blog/How much do Ozempic, Wegovy, Mounjaro and Zepbound cost in Canada?
CACanada Prices and costs

How much do Ozempic, Wegovy, Mounjaro and Zepbound cost in Canada?

Official prices only: Ontario’s drug plan list, the federal drug agency’s review and the maker’s list prices as reported in the press. No pharmacy, clinic or coupon prices.

GLP Guidebook teamPublished 12 Oct 20269 min read18 sourcesWritten from published sources

Written for Canada. Reading from India? India version

The short answer

Official prices for a 4-week pen: Ozempic $227.94 and generic semaglutide $78.14 on Ontario’s drug plan list; Wegovy $388.64 in the 2025 federal review; Mounjaro and Zepbound $300 at 2.5 or 5 mg and $420 at 7.5 or 10 mg, Lilly’s list prices from 29 December 2025 as reported by The Globe and Mail. Pharmacies set their own cash prices.

Key takeaways

  • Ontario’s drug plan lists an Ozempic pen at $227.94 and a generic semaglutide pen at $78.14, and pays the generic price for both.1
  • Canada’s Drug Agency used $388.64 for a Wegovy pen, the same at every dose, or $5,066 a year.2
  • The Globe and Mail reported that Eli Lilly would cut Mounjaro and Zepbound to $300 for 4 weeks of 2.5 or 5 mg and $420 for 7.5 or 10 mg, from 29 December 2025.3
  • Most of these pens hold 4 weekly doses, so a year of weekly injections uses 13 pens, not 12.4,5,2
  • Savings-card prices are not list prices, and Novo Nordisk’s Ozempic card does not apply in Quebec.6
Before you go further
  • GLP‑1 medicines are prescription drugs in Canada. Nothing here is a reason to start, stop or switch one.7
  • We name brands and official prices as facts. We don’t recommend, rank or link to any brand, pharmacy, clinic or program.
  • Ozempic, its generics and Mounjaro are approved for type 2 diabetes. Using them for weight loss is off-label (outside the approved use).4,8
  • The risks are the same however you get the medicine: see our side effects guide.
On this page
  1. What does one pen contain?
  2. What are the official prices?
  3. Why is generic semaglutide about a third of Ozempic’s price?
  4. What does a year cost at these prices?
  5. Who actually pays?
  6. Questions people ask
  7. How we researched this
  8. Sources

What does one pen contain?

Four weekly doses, for most pens: Ozempic, its generics, Wegovy FlexTouch, Mounjaro KwikPen and Zepbound KwikPen.4,2,8,5

That makes one pen roughly a month. A year of weekly doses needs 52 doses, which is 13 pens.

Two exceptions hold one dose each. Wegovy now also comes as a single-use pen, and Mounjaro also comes as a single-dose pen or vial.9,8 In Canada, Zepbound comes only as the 4-dose KwikPen.5

The price of a pen often doesn’t change with the dose inside it. Canada’s Drug Agency noted that Wegovy pens cost the same “for all doses”.2

What are the official prices?

These are the published figures we could find, each with its source and date. We found no published price for Mounjaro or Zepbound at 12.5 or 15 mg.

Medicine and doseOfficial priceSource
Ozempic Semaglutide, any listed pen$227.94 a penOntario formulary, 12 Oct 2026
Generic semaglutide Apotex or Dr. Reddy’s$78.14 a penOntario formulary, 12 Oct 2026
Rybelsus Semaglutide tablets$7.53 a tabletOntario formulary, 12 Oct 2026
Wegovy Semaglutide, any dose$388.64 a penCanada’s Drug Agency, 2025
Sevmia Generic Wegovy, 1 mg pen$325.05 a penOntario formulary (not a benefit), 12 Oct 2026
Mounjaro or Zepbound 2.5 or 5 mg Tirzepatide$300 for 4 weeksLilly, as reported Dec 2025
Mounjaro or Zepbound 7.5 or 10 mg Tirzepatide$420 for 4 weeksLilly, as reported Dec 2025

Grouped by medicine, not ranked. Ontario prices rounded to the cent from the formulary’s 3- and 4-decimal figures. Sources: Ontario Drug Benefit Formulary; CDA-AMC SR0841; Benefits and Pensions Monitor reporting The Globe and Mail.

Sources for the rows: Ontario’s formulary1, the federal review2 and Lilly’s list prices as reported by The Globe and Mail.3

A formulary price is what a provincial plan recognizes for a product. A pharmacy sets its own cash price. Before generics arrived, Global News reported brand semaglutide at “hundreds of dollars a month”, in some cases over $450.10

Why is generic semaglutide about a third of Ozempic’s price?

Canada’s generic pricing framework sets a non-oral generic at 35% of the brand price once three or more generics exist, and Ontario’s price sits close to that tier.11,1

The pan-Canadian Pharmaceutical Alliance (pCPA), which negotiates drug prices for public plans, sets generic prices in tiers. With one generic the price is 75% to 85% of the brand; with two, 50%; with three or more, 35% for injections.11

Ontario’s $78.14 is 34% of Ozempic’s $227.94.1 Apotex said its generic would be “approximately one-third the price” of Ozempic.10

The maker responded. From late May 2026, Novo Nordisk offered a savings card to people without public or private coverage, “aligning their medication costs with generic alternatives”. The card excludes Quebec.6 We don’t show savings-card prices, because they are not list prices and the terms change.

Free toolWork out a 6- or 12-month cost

Pick a medicine and a dose plan, then add what your plan pays. No sign-up.

Open the calculator

What does a year cost at these prices?

At official prices, 13 pens of Ozempic come to about $2,963, generic semaglutide about $1,016, and Wegovy $5,066 a year by the federal agency’s count.1,2

$1,016Generic semaglutide, 13 pens at the Ontario price1
$2,963Ozempic, 13 pens at the Ontario price1
$5,066Wegovy, a year, Canada’s Drug Agency2
$5,220Mounjaro or Zepbound, stepping up to 10 mg3

Our arithmetic, except Wegovy. Tirzepatide: one 4-week supply each at 2.5, 5 and 7.5 mg, then 10 at 10 mg: $300 + $300 + $420 + 10 × $420. Held at 5 mg, it is 13 × $300 = $3,900. Dispensing fees are left out.

Tirzepatide starts at 2.5 mg for 4 weeks, then goes up in 2.5 mg steps at least 4 weeks apart.5 Your prescriber may move more slowly or stop at a lower dose.

For context: in the 72-week SURMOUNT-1 trial, people on Zepbound 10 mg lost 19.5% of their weight on average. On a dummy injection, it was 3.1%.5 Results varied widely, and the harms are below.

RisksThe risks, in brief
  • Stomach effects. About 44 in 100 people on Wegovy 2.4 mg felt sick (nausea), against 16 in 100 on a dummy injection. On Zepbound 15 mg it was about 28 in 100, against about 9 in 100.9,5
  • Gallbladder. Gallstones affected about 16 in 1,000 people on Wegovy, against 7 in 1,000 on a dummy injection. An inflamed gallbladder affected about 6 in 1,000 on Zepbound, against 2 in 1,000.9,5
  • Pancreatitis (an inflamed pancreas): severe stomach pain that won’t go away, sometimes spreading to the back.9
  • Dehydration from vomiting or diarrhea can harm the kidneys.9
  • Thyroid and pregnancy. Not for anyone with a personal or family history of medullary thyroid cancer, or MEN 2. Canada’s obesity guideline advises against these medicines in pregnancy, while breastfeeding or when trying to conceive.5,12
Full detail in our side effects guide →
Get help now: call 911 or go to the nearest emergency department for severe stomach pain that won’t go away, with or without vomiting. It can be pancreatitis. Not sure? Call 811 to speak to a nurse in most provinces (Info-Santé 811 in Quebec).9,13

Who actually pays?

Public drug plans cover semaglutide for type 2 diabetes, with conditions. As of 12 October 2026, none covers any GLP‑1 for weight management.14,15,16

Each province and territory runs its own plan. The plan-by-plan detail is in does your province cover Ozempic?, and the weight-loss story in why no province covers Wegovy or Zepbound.

Private plans vary. In a 2026 survey, 37% of Canadian employers covered GLP‑1s for weight loss as well as diabetes.17 See private insurance and GLP‑1s.

Advertised prices you see online are a seller’s own. Canadian law lets a prescription drug be advertised to the public only by name, price and quantity.18

Questions people ask

How much is Ozempic in Canada without insurance?

Ontario’s drug plan lists an Ozempic pen, 4 weekly doses, at $227.94. Pharmacies set their own cash prices; Global News reported brand semaglutide at hundreds of dollars a month, sometimes over $450, before generics arrived.1,10

How much is generic semaglutide in Canada?

Ontario’s formulary lists Apo-Semaglutide and Dr. Reddy’s pens at $78.14 each, about a third of the Ozempic price.1

How much is Mounjaro in Canada?

The Globe and Mail reported that Lilly would set Mounjaro and Zepbound at $300 for 4 weeks of 2.5 or 5 mg and $420 for 7.5 or 10 mg from 29 December 2025; Reuters could not verify the report at the time. We found no published price for 12.5 or 15 mg.3

Is Wegovy more expensive than Ozempic?

Per pen, Canada’s Drug Agency used $388.64 for Wegovy, while Ontario lists Ozempic at $227.94. A Wegovy pen costs the same at every dose.2,1

Why does my pharmacy charge a different price?

Formulary prices are what a plan recognizes. Each pharmacy sets its own cash price and dispensing fee, so the till price can differ from the official figure.1

How we researched this

We used official figures only: Ontario’s Drug Benefit Formulary (checked 12 October 2026), Canada’s Drug Agency’s 2025 Wegovy review, and Lilly’s prices as reported by The Globe and Mail. We show no pharmacy, clinic or coupon price.

Year totals are our arithmetic, at 13 pens a year.

Before you move on

  • Price the whole dose ladder, not the first pen.
  • Count 13 pens a year, not 12.
  • Ask your plan what it pays before you fill it.
  • Ask the pharmacy for its dispensing fee.
  • Treat a coupon price as temporary.
Cost calculatorGetting a prescription, and the medicinesConsidering it for weight

More from the Canada blog

CACanadaWhich generic versions of Ozempic and Wegovy are approved in Canada?CACanadaDoes your province cover Ozempic? Ontario, BC, Alberta, Quebec and others comparedCACanadaDoes private insurance cover Ozempic, Wegovy or Zepbound in Canada?
About GLP Guidebook

The monthly Canada update

An independent guide to GLP‑1 medicines. We don’t sell medicines, take drug-company money, earn commissions or link to any provider. Once a month: Health Canada approvals, recalls, provincial coverage changes and official prices. How we write

Was this post easy to understand?

Sources

  1. Ontario Ministry of Health. Ontario Drug Benefit Formulary search, semaglutide rows (Ozempic $227.94 per pen with $78.141 paid; Apo-Semaglutide and Dr. Reddy’s $78.141; Sevmia $325.048, off-formulary interchangeable; Wegovy off-formulary interchangeable, no price; Rybelsus $7.5303 per tablet; no tirzepatide row). Checked 12 October 2026. Link
  2. Canada’s Drug Agency (CDA-AMC). Semaglutide (Wegovy) SR0841 clinical and pharmacoeconomic review (“The unit cost is $388.64 per pen (or $97.16 per dose)”; annual cost $5,066; Ozempic $2,844 to $5,688 a year). 2025. Link
  3. Benefits and Pensions Monitor, reporting The Globe and Mail. Eli Lilly cuts Canadian obesity drug prices (Mounjaro and Zepbound, from 29 December 2025: $300 for a four-week supply of 2.5 or 5 mg; $420 for 7.5 or 10 mg). 19 December 2025. Link
  4. Novo Nordisk Canada. Ozempic (semaglutide injection) Product Monograph, 13 July 2026 (produced by recombinant DNA technology in yeast; 2, 4 and 8 mg pens; indications; adverse reactions table; pancreatitis; contraindications). PDF
  5. Eli Lilly Canada. Zepbound (tirzepatide injection) Product Monograph, date of authorization 11 June 2026 (indications; “The ZEPBOUND multi-dose KwikPen contains 4 doses”; doses; SURMOUNT-1 and -2 results and adverse reactions; coadministration with Mounjaro not recommended; contraindications). PDF
  6. Global News. Novo Nordisk to cut Ozempic price as generics arrive (savings card excluding Quebec; “only a small number of private insurers cover the use of the drugs for weight management”; Alberta step therapy; Ontario Limited Use). 26 May 2026. Link
  7. Health Canada. Drug Product Database: status records for every semaglutide product (Ozempic, Rybelsus, Wegovy, Plosbrio, Poviztra; generics from Dr. Reddy’s, Apotex, Aspen and Sandoz, and Sevmia). Searched 12 October 2026. Link
  8. Eli Lilly Canada. Mounjaro (tirzepatide injection) Product Monograph, date of authorization 23 June 2026 (type 2 diabetes in adults and in ages 10 to under 18; single-dose pen, vial and 4-dose KwikPen; storage). PDF
  9. Novo Nordisk Canada. Wegovy (semaglutide injection) Product Monograph, date of authorization 2 October 2026 (indications; dose escalation; STEP 1–3 results and adverse reactions; pancreatitis, gallbladder, kidney and pregnancy warnings; storage). PDF
  10. Global News / The Canadian Press. Generic semaglutide sales begin in Canada. 20 May 2026. Link
  11. Patented Medicine Prices Review Board (NPDUIS). Generic and biosimilar pricing policies: pCPA tiered framework (three or more generics: “25% … for oral solids; 35% for non-oral solids”). 15 January 2024. Link
  12. Pedersen SD, Manjoo P, Dash S, Jain A, Pearce N, Poddar M. Canadian Adult Obesity Clinical Practice Guideline: Pharmacotherapy for Obesity Management in Adults, 2025 update. Obesity Canada, Version 3, 11 August 2025 (recommendations 1–13; six medicines approved for obesity; off-label use discouraged; pregnancy). PDF
  13. Heart and Stroke Foundation of Canada. Medical services by phone (811 in most provinces and Yukon; Info-Santé 811 in Quebec; other numbers in Manitoba, the Northwest Territories and Nunavut). Checked 12 October 2026. Link
  14. BC PharmaCare. Limited coverage drugs: semaglutide (Special Authority after inadequate control on maximum tolerated metformin; approval indefinite; up to 1 mg weekly; 2 mg under review). Updated 21 April 2026. Link
  15. BC PharmaCare. Drug coverage decision: semaglutide (Wegovy), “Non-benefit”, 18 December 2025 (pCPA negotiations concluded without agreement on 1 December 2025; Novo Nordisk no longer seeking public coverage; generic semaglutide to be reviewed). PDF
  16. Ontario Ministry of Health. Executive Officer notice: Ozempic listed with Limited Use codes 665–667 (for adults with type 2 diabetes when control is not achieved on the maximum tolerated dose of metformin, or metformin is contraindicated or inappropriate; authorization period indefinite). 26 January 2024. PDF
  17. International Foundation of Employee Benefit Plans. GLP-1 drug trends: Canadian employers continue to increase coverage for weight loss (2026 pulse survey). 7 July 2026. Link
  18. Food and Drug Regulations, C.R.C., c. 870, section C.01.044 (advertising a prescription drug to the public is limited to “the brand name, the proper name, the common name and the price and quantity”). Current to 21 September 2026. Link

Last checked 12 Oct 2026 · Next review due 12 Apr 2027 · Report an error

How this post was made. Written by the GLP Guidebook team from the sources above. It’s general information, not medical advice. Talk to your family doctor, nurse practitioner or pharmacist before starting, stopping or changing any medicine. We don’t sell, prescribe or recommend any brand or provider. How we write